E. Cutsem

发表

3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer

F. Lordick, L. Shen, E. Kulikov, 2007 .

FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

E. Van Cutsem, M. Borad, G. Abou-Alfa, 2019, Annals of Oncology.

195TiP GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

J. Ajani, Y. Bang, Ruifeng Xu, 2020 .

198TiP SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)

J. Ajani, Y. Bang, Ruifeng Xu, 2020 .

O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies

J. Tabernero, J. Tie, T. George, 2021, Annals of Oncology.

LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study

J. Ajani, T. Zander, A. Lièvre, 2020 .

197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859

J. Tabernero, Y. Janjigian, S. Qin, 2020, Annals of Oncology.

O-10 ANCHOR CRC: Results from a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E–mutant metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, R. Yaeger, 2021, Annals of Oncology.

Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies

D. Jäger, P. Ascierto, M. Maio, 2019, Annals of Oncology.

Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062

Y. Bang, J. Tabernero, Z. Wainberg, 2019, Annals of Oncology.

Patient acceptance for CT colonography: what is the real issue?

G. Marchal, S. Dymarkowski, E. Van Cutsem, 2002, European Radiology.

European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication

J. Cuzick, H. Brenner, E. Kuipers, 2012, Endoscopy.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

J Ricke, T Maughan, W. Oyen, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

E. Van Cutsem, B. Nordlinger, A. Cervantes, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.

E. Van Cutsem, S. Segaert, E. Cutsem, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

V. Georgoulias, E. Van Cutsem, J. Canon, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer.

L. Mortelmans, A. Maes, L. Mortelmans, 2000, The Journal of thoracic and cardiovascular surgery.

O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study

M. Shah, J. Tabernero, M. Fakih, 2021, Annals of Oncology.

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

R. Labianca, D. Kerr, I. Nagtegaal, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†

Y. Shimada, E. Van Cutsem, N. Sugimoto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Etoposide, leucovorin and 5-fluorouracil in advanced gastric cancer: a phase II study.

E. Van Cutsem, F. Penninckx, L. Filez, 1995, Anticancer research.

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.

M. Ychou, E. Van Cutsem, B. Nordlinger, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification

Y. Bang, E. Van Cutsem, D. Cunningham, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab + low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.

M. Sawyer, E. Van Cutsem, B. Neyns, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials †

J. Pignon, E. Van Cutsem, J. Tabernero, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

E. Van Cutsem, T. Seufferlein, P. Rougier, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).

J. Ledermann, E. Van Cutsem, B. Nordlinger, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil.

E. Van Cutsem, P. Hoff, B. Osterwalder, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

The role of chemotherapy in biliary tract carcinoma.

E. Van Cutsem, C. Verslype, H. Prenen, 2008, HPB : the official journal of the International Hepato Pancreato Biliary Association.

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

E. Van Cutsem, Y. Humblet, S. Tejpar, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

E. Van Cutsem, D. V. Von Hoff, H. van de Velde, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial.

E. Van Cutsem, F. Lordick, A. Sawaki, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

E. D. de Vries, E. Van Cutsem, M. Välimäki, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

R. Labianca, D. Kerr, K. Haustermans, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study

E. Van Cutsem, R. Kelley, C. Verslype, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

E. Van Cutsem, M. Alsina, M. Lichinitser, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

E. Van Cutsem, A. Santoro, J. Douillard, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.

E. Van Cutsem, B. Nordlinger, A. Cervantes, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

R. Schilsky, E. Van Cutsem, J. Marshall, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.

R. Labianca, K. Haustermans, E. Van Cutsem, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.

A. Tres, E. Van Cutsem, D. Crivellari, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

Jun Yu Li, E. Baba, E. Van Cutsem, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival

J. Berlin, A. Biankin, P. Philip, 2021, Annals of Oncology.

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

E. Van Cutsem, J. Tabernero, M. Makrutzki, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.

C. Sempoux, J. Machiels, K. Haustermans, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

C. Bokemeyer, E. Van Cutsem, C. Köhne, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Pooled analysis of the surgical treatment for colorectal cancer liver metastases.

E. Van Cutsem, P. Flamen, C. Rolfo, 2015, Critical reviews in oncology/hematology.

Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial

O. Gevaert, A. Debucquoy, K. Haustermans, 2015, British Journal of Cancer.

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.

R. Labianca, D. Kerr, P. Johnston, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

C. Boni, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

E. Van Cutsem, H. Lenz, J. Stoehr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

R. Greil, S. Kubicka, E. Van Cutsem, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype: a progenitor cell tumour?

E. Van Cutsem, T. Roskams, R. De vos, 2008, Liver.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Pancreatic cancer treatment and research: an international expert panel discussion.

J. Berlin, E. Van Cutsem, M. Ducreux, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer.

L. Mortelmans, A. Maes, L. Mortelmans, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III POLO trial

M. Reni, G. Tortora, D. Hochhauser, 2020 .

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

R. Labianca, D. Kerr, J. Berlin, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009.

E. Van Cutsem, J. Tabernero, D. Haller, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

R. Labianca, J. Berlin, K. Haustermans, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.

E. Van Cutsem, G. Bodoky, M. Bass, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer.

A. Bottomley, M. Koller, T. Conroy, 2004, European journal of cancer.

Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies

M. Ychou, A. Grothey, H. Lenz, 2012 .

Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival.

T. Gorlia, T. Conroy, E. Van Cutsem, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.

P. Dupont, L. Mortelmans, G. Bormans, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of diagnostic accuracy of 111In-pentetreotide SPECT and 68Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours

K. Nackaerts, F. Mottaghy, L. Mortelmans, 2016, European Radiology.

A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.

E. Van Cutsem, L. Dirix, Y. Humblet, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER).

R. Greil, J. Slotta-Huspenina, E. Van Cutsem, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Visualization and characterization of gastric contractions using a radionuclide technique.

S. Mayeur, E. Van Cutsem, J. Siegel, 1990, The American journal of physiology.

Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET).

L. Mortelmans, A. Maes, L. Mortelmans, 2001, European journal of cancer.

Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).

M. Piccart, K. Mcgregor, R. Stahel, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.

M. Ychou, B. Nordlinger, T. Gruenberger, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

W. Oyen, R. Labianca, W. Scheithauer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

E. Van Cutsem, M. Moore, T. Ciuleanu, 2014, British Journal of Cancer.

Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma

J. Ajani, E. Van Cutsem, D. Ferry, 2006, British Journal of Cancer.

R. Greil, S. Kubicka, M. Makrutzki, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

COST-EFFECTIVENESS OF CETUXIMAB IN COMBINATION WITH IRINOTECAN COMPARED WITH CURRENT CARE IN METASTATIC COLORECTAL CANCER AFTER FAILURE ON IRINOTECAN – A BELGIAN ANALYSIS

E. Van Cutsem, Y. Humblet, L. Annemans, 2007, Acta clinica Belgica.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

F. Lordick, M. Ducreux, Y. Hotko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

W. Scheithauer, E. Van Cutsem, B. Neyns, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

M. Caraglia, E. Van Cutsem, F. Ciardiello, 2012, British Journal of Cancer.

Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2).

E. Van Cutsem, E. Lin, J. Hecht, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HIPEC in T4a colon cancer: a defendable treatment to improve oncologic outcome?

E. Van Cutsem, A. Wolthuis, S. Fieuws, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.

C. Bokemeyer, E. Van Cutsem, J. Tabernero, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

E. Van Cutsem, H. Lenz, B. Neyns, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Salazar, P. Laurent-Puig, E. Van Cutsem, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial.

E. Van Cutsem, B. Nordlinger, M. Ducreux, 2005, European journal of cancer.

POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

M. Reni, G. Tortora, D. Hochhauser, 2019, Annals of Oncology.

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

E. Van Cutsem, J. Tabernero, C. Allegra, 2013, British Journal of Cancer.

Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

S. Hitier, P. Follana, A. Zaniboni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

E. Van Cutsem, E. Raymond, A. Vinik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.

P. Rougier, C. Schmitt, E. Cutsem, 1999, Anti-cancer drugs.

Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study

E. Van Cutsem, L. Dirix, M. Borner, 2005, British Journal of Cancer.

E. Van Cutsem, M. Amonkar, D. Smith, 2020, Annals of Oncology.

Impact of pembrolizumab (pembro) versus paclitaxel on health-related quality of life (HRQoL) in patients with advanced gastric or gastroesophageal junction (GEJ) cancer that has progressed after first-line chemotherapy (KEYNOTE-061)

Z. Wainberg, M. Alsina, M. Amonkar, 2019, Annals of Oncology.

Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.

C. Sotiriou, M. Piccart, P. Laurent-Puig, 2015, Cancer treatment reviews.

561P Phase Ib study of ribociclib (R) + trametinib (T) in patients (pts) with metastatic/advanced solid tumours

J. Desai, G. Shapiro, A. Boran, 2020 .

Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

M. Lacouture, E. Van Cutsem, F. Ciardiello, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant treatment of colorectal cancer (current expert opinion derived from the Third International Conference: Perspectives in Colorectal Cancer, Dublin, 2001).

R. Labianca, D. Kerr, P. Johnston, 2002, European journal of cancer.

Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): Results of the primary analysis.

V. Moiseenko, R. Glynne-Jones, N. Amellal, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.